Treatment-related toxicities encountered during induction and consolidation intensive chemotherapy cycles
| . | Induction number (%), n = 35 . | Subsequent cycles number (%), n = 31 . | ||
|---|---|---|---|---|
| Grade 1/2 . | Grade 3/4 . | Grade 1/2 . | Grade 3/4 . | |
| Infections | 1 (3) | 24 (69) | 1 (3) | 26 (84) |
| Pleural effusions | 1 (3) | 1 (3) | 5 (16) | 1 (3) |
| Hemorrhage | NA | 4 (11) | 1 (3) | 11 (35) |
| Gastrointestinal | 14 (40) | 1 (3) | 3 (10) | NA |
| Cardiac | 3 (9) | 1 (3) | 2 (6) | 1 (3) |
| Renal failure | NA | 6 (17) | NA | 4 (13) |
| Metabolic | 22 (63) | 21 (60) | 9 (29) | 11 (35) |
| Increased AST/ALT | 4 (11) | 3 (9) | 2 (6) | 1 (3) |
| Neurological | 2 (6) | NA | 2 (6) | 1 (3) |
| DVT/PE | 1 (3) | NA | 3 (10) | 4 (13) |
| . | Induction number (%), n = 35 . | Subsequent cycles number (%), n = 31 . | ||
|---|---|---|---|---|
| Grade 1/2 . | Grade 3/4 . | Grade 1/2 . | Grade 3/4 . | |
| Infections | 1 (3) | 24 (69) | 1 (3) | 26 (84) |
| Pleural effusions | 1 (3) | 1 (3) | 5 (16) | 1 (3) |
| Hemorrhage | NA | 4 (11) | 1 (3) | 11 (35) |
| Gastrointestinal | 14 (40) | 1 (3) | 3 (10) | NA |
| Cardiac | 3 (9) | 1 (3) | 2 (6) | 1 (3) |
| Renal failure | NA | 6 (17) | NA | 4 (13) |
| Metabolic | 22 (63) | 21 (60) | 9 (29) | 11 (35) |
| Increased AST/ALT | 4 (11) | 3 (9) | 2 (6) | 1 (3) |
| Neurological | 2 (6) | NA | 2 (6) | 1 (3) |
| DVT/PE | 1 (3) | NA | 3 (10) | 4 (13) |
AST/ALT indicates aspartate aminotransferase/alanine aminotransferase; DVT/PE, deep vein thrombosis/pulmonary embolism; and NA, not applicable.